Key Findings:  The authors analyzed data from 436 hemodialysis patients. They discovered that patients with higher serum 2-AG had lower 12-month all-cause mortality risks compared to the group with lower serum 2-AG, leading the authors to hypothesize that circulating endocannabinoid level may be used as a predictor for mortality in this patient population.
Type of Study:  Meta-analysis
Study Sample Size:  436
Study Result:  Positive
Study Location(s):  Israel
Year of Pub:  2023
Cannabinoids Studied:  Anandamide (AEA), 2-Arachidonoyl Glycerol (2-AG)
Phytocannabinoid Source:  Not Applicable